Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

Leading experts in spinal muscular atrophy (SMA) explore factors influencing treatment decision-making with approved SMA therapies using three patient case studies.

Watch here:

This activity is funded by an independent medical education grant from Biogen and Novartis Gene Therapies. This activity is jointly provided by USF Health and touchIME.
Be the first to comment